The adjuvants market for the vaccine was estimated at USD 665.86 million by 2020, and is expected to grow by a CAGR of 13.37% over the forecast period.
During the COVID-19 epidemic, as imports and exports are limited due to job closures, it is expected to have a short-term impact on the study market due to shortages and unavailability of products. However, this may allow local producers to increase their presence in the market. Disruption of supply and shortage of products has been observed in several countries due to the temporary closure of production facilities. According to a research article in Nature Reviews Immunology 2020, vaccine adjuvants based on aluminum provide a smooth finish to high levels of neutral antibody, increasingly recognized as a protective stone provided by the COVID-19 vaccines. In addition, by May 2020, GSK aimed to produce 1 billion volumes of its adjuvant epidemic vaccine program by 2021 to support the development of more people to vaccinate COVID-19. Therefore, the COVID-19 epidemic is expected to have a positive impact on the market growth studied.
Factors that promote the growth of the adjuvants vaccine market include unmet demand for specific vaccines, increasing government vaccination recommendations, technological advances, and increased use of combined and synthetic vaccines.
Globally, various government agencies are promoting and raising awareness about vaccinations against various diseases, such as anthrax, BCG, hepatitis, HPV, influenza, varicella, smallpox, and other conditions. In March 2021, the United States Department of Health and Human Services (HHS) invested nearly USD 10 billion to increase access to vaccines and better help communities of color, rural, low income, and other marginalized communities in response to COVID-19. Such government initiatives on immunization in the country increase the use of vaccines and have a positive impact on the market.
The adjuvant market is gaining momentum from the increasing use of integrated unit vaccines. As consumption increases, the demand for various adjuvants is growing. In the coming years, more development is expected, which increases the demand for adjuvants. The market is expected to grow at a moderate rate, particularly driven by the increasing adoption of biologics and biosimilars and the rise of R&D in vaccines worldwide.
Poisoning is one of the most important obstacles in introducing the majority of adjuvants used by humans. Toxins can also increase the financial burden on market players during the development and production stages. Therefore, the adverse effects of adjuvant toxicity on vaccine production costs and vaccine safety profiles are hampering market growth.
Key Market Trends
The Mineral Salt-based Adjuvants Segment is Expected to Witness the Highest CAGR During the Forecast Period
Part of the mineral salt-based adjuvants are expected to prove significant growth over the forecast period. Alum vaccine supplements are the most widely used adjuvants in human vaccines. Aluminum salts include aluminum hydroxide, aluminum phosphate, and aluminum hydroxyphosphate. Aluminum-based salt is also used for research purposes to increase the effectiveness of vaccines. Besides alum, calcium salts, iron, and zirconium are also frequently used as alternatives to alum salt. Calcium phosphate is regularly used in vaccines for diphtheria-tetanus-pertussis (DTP), polio, yellow fever, and BCG. It advertises soluble antigens and secretly expresses them in the immune system. According to a research article published in 2020, the development of mineral salt-based adjuvants continues to improve the adjuvant activity of aluminum adjuvants, which includes the use of nano-aluminum additives to enhance antigen.
Additionally, in June 2020, Clover Biopharmaceuticals AUS Pty Ltd launched a Phase 1 COVID-19 clinical trial with the SCB-2019 vaccine and Alum adjuvant to test the safety, reactogenicity, and immune function of SCB-2019 at multiple dosage levels, administered as two injections, intramuscularly in healthy subjects. Therefore, ongoing research activities and the many benefits of salt-based adjuvants in the vaccine, especially in the development of COVID-19 vaccines, are expected to further market growth in the forecast period.
North America Holds a Significant Share in the Market During the Forecast Period
North America is expected to see significant growth in the market studied during the forecast period. The main factors driving the growth of the adjuvants market for the North American region are the presence of key market players, the availability of advanced technology, and the growing cost of vaccination R&D.
According to the Centers for Disease Control and Prevention (CDC) estimates, about 16 diseases can now be prevented with child vaccines, and the general vaccination of American children born between 1994-2018 has prevented more than 419 million diseases, hospitalization of 26.8. , and 936,000 premature deaths.
According to the Centers for Disease Control and Prevention (CDC), adjuvants such as aluminum hydroxyphosphate sulfate, monophosphoryl lipid A (MPL) + aluminum salts, oil-based emulsions made from squalene, MPL, and -QS-21 (a natural compound from the Chilean soap tree incorporated in liposomal formulation), and cytosine phosphoguanine (CpG) is currently used in vaccines such as DtaP (Daptacel, Infanrix), Hep A (Havrix, Vaqta), Hep B (Engerix-B, Recombivax), HPV (Gardasil 9), Pneumococcal (Prevnar 13), Cervarix, Fluad, Shingrix, and Heplisav-B in the United States. In addition, there has been a growing interest in adjuvant technology for the development of the vaccine COVID-19, and this trend is expected to further the market growth learned in the region during the violence.
In addition, according to the National Clinical Trials (NCT) Registry, as of September 21, 2020, in the United States, approximately 500 vaccine clinical trials are under development, which are expected to have a positive impact on the study market for these services. They are effective in increasing or activating the immune system. Therefore, ongoing clinical trials related to vaccine development and high-quality research activities in the United States are expected to further the market growth studied in North America in the forecast period.
The vaccine adjuvants market is moderately consolidated and consists of many major players. Companies such as Adjuvatis, GlaxoSmithKline PLC, Croda International PLC, Merck KGaA, and Novavax Inc. are the key players. The major companies have conducted product launches, approvals, acquisitions, and collaborations for the development of novel vaccine adjuvants, thereby building a competitive landscape in the market. For instance, in April 2020, GlaxoSmithKline PLC collaborated with Sanofi to develop an adjuvanted vaccine for COVID-19. Also, in the coming years, few other players are expected to enter the market owing to the high scope of expansion in the product portfolio globally.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Expanding Government Recommendations for Immunizations
4.2.2 Unmet Vaccine Market Needs for Certain Diseases
4.2.3 Increasing Use of Recombinant Subunit and Synthetic Vaccines
4.3 Market Restraints
4.3.1 Side Effects and High Toxicity of Adjuvants
4.3.2 High R&D Cost of Developing a New Adjuvant
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Mineral Salt-based Adjuvant
5.1.2 Tensoactive Adjuvants
5.1.3 Adjuvant Emulsions
5.1.4 Liposome Adjuvants
5.1.5 Carbohydrate Adjuvants
5.1.6 Bacteria-derived Adjuvants
5.1.7 Virus-like Particles (VLP)
5.1.8 Other Types
5.2 By Usage
5.2.1 Active Immunostimulants
5.2.3 Vehicle Adjuvants
5.3 By Disease Type
5.3.1 Infectious Disease
5.4 By Application
5.4.1 Research Applications
5.4.2 Commercial Applications
5.5.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.5.5 South America
188.8.131.52 Rest of South America
6.1.1 Adjuvance Tecchnologies Inc.
6.1.3 Agenus Inc.
6.1.4 Aphios Corporation
6.1.5 Chemtrade Logistics Inc.
6.1.6 Croda International PLC (Brenntag Biosector AS)
6.1.7 CSL Limited
6.1.8 Dynavax Technologies Corporation
6.1.9 GlaxoSmithKline PLC
6.1.11 Merck KGaA
6.1.12 Novavax Inc.
6.1.13 OZ Biosciences
6.1.14 Pacific GeneTech Limited
6.1.15 Seppic (Air Liquide)
6.1.16 Thermo Fisher Scientific Inc.
A selection of companies mentioned in this report includes:
- Adjuvance Tecchnologies Inc.
- Agenus Inc.
- Aphios Corporation
- Chemtrade Logistics Inc.
- Croda International PLC (Brenntag Biosector AS)
- CSL Limited
- Dynavax Technologies Corporation
- GlaxoSmithKline PLC
- Merck KGaA
- Novavax Inc.
- OZ Biosciences
- Pacific GeneTech Limited
- Seppic (Air Liquide)
- Thermo Fisher Scientific Inc.